Milestone Asset Management LLC Acquires 5,828 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Milestone Asset Management LLC grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 21.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,777 shares of the biotechnology company’s stock after buying an additional 5,828 shares during the quarter. Milestone Asset Management LLC’s holdings in Exelixis were worth $1,091,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC bought a new stake in Exelixis during the 3rd quarter worth about $30,000. USA Financial Formulas acquired a new position in shares of Exelixis during the 4th quarter worth about $32,000. Brooklyn Investment Group acquired a new position in shares of Exelixis during the 3rd quarter worth about $42,000. UMB Bank n.a. increased its stake in shares of Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 553 shares during the last quarter. Finally, Capital Performance Advisors LLP acquired a new position in shares of Exelixis during the 3rd quarter worth about $61,000. 85.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

EXEL has been the topic of several recent analyst reports. BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. The Goldman Sachs Group upgraded shares of Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. TD Cowen boosted their price objective on shares of Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. JMP Securities reiterated a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus upped their price target on shares of Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and a consensus target price of $36.06.

Insider Transactions at Exelixis

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This represents a 10.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Dana Aftab sold 96,986 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $3,394,510.00. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $17,463,075. The trade was a 16.27 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 288,574 shares of company stock valued at $10,102,874. Company insiders own 2.85% of the company’s stock.

Exelixis Trading Up 1.1 %

Shares of Exelixis stock opened at $32.96 on Thursday. The company has a 50 day moving average of $34.77 and a 200-day moving average of $29.99. Exelixis, Inc. has a 1-year low of $20.01 and a 1-year high of $37.59. The company has a market cap of $9.41 billion, a PE ratio of 21.13, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same quarter in the prior year, the firm posted $0.10 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. Research analysts forecast that Exelixis, Inc. will post 1.74 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.